Abstract
Allergic diseases emerge as a substantial health problem of the 21st century. Current therapies including combination therapies of corticosteroids and β2-agonists are highly effective, inexpensive and relatively safe. However, these medicaments only relieve symptoms but are not curing disease. So the challenge has to be to develop new therapeutics which are as effective as present medicaments without any side effects and hopefully even heal the disease. It has become clear over the past years that Th2-cells and their cytokines have an outstanding role in the development of airway hyperresponsiveness, airway inflammation, airway remodelling and reversible airway obstruction, the cardinal symptoms of allergic asthma. There is legitimate hope that down regulation of these factors could result in a susceptible damage of pathologic mechanisms. Out of different gene silencing techniques RNAi seems to be the most promising method to achieve long-lasting and effective abrogation of key elements in allergic diseases. In particular, this review will highlight the potential of small interfering RNAs to specifically inhibit the function of transcription factors and tyrosine kinases which are involved in orchestrating an allergic immune response.
Keywords: Allergy, asthma, siRNA, transcription factors
Current Molecular Medicine
Title: Targeting Allergic Airway Diseases by siRNA: An Option for the Future?
Volume: 9 Issue: 4
Author(s): Holger Meinicke, Yasemin Darcan and Eckard Hamelmann
Affiliation:
Keywords: Allergy, asthma, siRNA, transcription factors
Abstract: Allergic diseases emerge as a substantial health problem of the 21st century. Current therapies including combination therapies of corticosteroids and β2-agonists are highly effective, inexpensive and relatively safe. However, these medicaments only relieve symptoms but are not curing disease. So the challenge has to be to develop new therapeutics which are as effective as present medicaments without any side effects and hopefully even heal the disease. It has become clear over the past years that Th2-cells and their cytokines have an outstanding role in the development of airway hyperresponsiveness, airway inflammation, airway remodelling and reversible airway obstruction, the cardinal symptoms of allergic asthma. There is legitimate hope that down regulation of these factors could result in a susceptible damage of pathologic mechanisms. Out of different gene silencing techniques RNAi seems to be the most promising method to achieve long-lasting and effective abrogation of key elements in allergic diseases. In particular, this review will highlight the potential of small interfering RNAs to specifically inhibit the function of transcription factors and tyrosine kinases which are involved in orchestrating an allergic immune response.
Export Options
About this article
Cite this article as:
Meinicke Holger, Darcan Yasemin and Hamelmann Eckard, Targeting Allergic Airway Diseases by siRNA: An Option for the Future?, Current Molecular Medicine 2009; 9 (4) . https://dx.doi.org/10.2174/156652409788167041
DOI https://dx.doi.org/10.2174/156652409788167041 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Predictors of Drug Hypersensitivity
Current Pharmaceutical Design Biological Characteristics and Role of Histamine in Case of Allergic Rhinitis
Medicinal Chemistry Reviews - Online (Discontinued) Editorial (Thematic Issue: Contemporary siRNA Therapeutics and the Current State-of-Art)
Current Pharmaceutical Design Obesity and Diabetes Gene Discovery Approaches
Current Pharmaceutical Design Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Preface (Hot Topic: Pulmonary Inflammation Guest Editor: Momtchilo Russo)
Current Drug Targets - Inflammation & Allergy Bronchial Thermoplasty: Burn to Cure?
Current Respiratory Medicine Reviews Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Nuclear Factor Kappa B is a Promising Therapeutic Target in Inflammatory Lung Disease
Current Drug Targets Nanocarriers Made from Non-Ionic Surfactants or Natural Polymers for Pulmonary Drug Delivery
Current Pharmaceutical Design Editorial [Hot Topic: Animal Models of Asthma (Guest Editor: Armin Braun)]
Current Drug Targets Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Association of Wheat Allergy and Coeliac Disease through Pediatric and Adult Age: A Review of Literature
Current Nutrition & Food Science Increased Fetal Cardiovascular Disease Risk: Potential Synergy Between Gestational Diabetes Mellitus and Maternal Hypercholesterolemia
Current Vascular Pharmacology Human Endotoxemia as a Model of Systemic Inflammation
Current Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery